Ethyl isocyanate → HCID 58529496, 화합물
반응식
[CH2:1]([C:8]1[S:9][C:10]2[CH:16]=[CH:15][C:14]([C:17]3[CH:18]=[C:19]([CH:27]4[CH2:32][CH2:31][NH:30][CH2:29][CH2:28]4)[N:20]4[C:25]=3[C:24]([NH2:26])=[N:23][CH:22]=[N:21]4)=[CH:13][C:11]=2[N:12]=1)[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1.[CH2:33]([N:35]=[C:36]=[O:37])[CH3:34]>>[NH2:26][C:24]1[C:25]2=[C:17]([C:14]3[CH:15]=[CH:16][C:10]4[S:9][C:8]([CH2:1][C:2]5[CH:3]=[CH:4][CH:5]=[CH:6][CH:7]=5)=[N:12][C:11]=4[CH:13]=3)[CH:18]=[C:19]([CH:27]3[CH2:32][CH2:31][N:30]([C:36]([NH:35][CH2:33][CH3:34])=[O:37])[CH2:29][CH2:28]3)[N:20]2[N:21]=[CH:22][N:23]=1참가 물질
3
실험 절차
In a manner similar to the procedure described for the preparation of Example 331 and using 5-(2-benzyl-1,3-benzothiazol-5-yl)-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine and ethylisocyanate as starting material, 7 mg (12%) of the desired product was isolated.
후처리
- customIn a manner similar to the procedure described for the preparation of Example 331
출처 및 근거
- ORD 기록
- ord-52eb93be15614e85aad9470575590472
- 출처 데이터셋
- uspto-grants-2013_04
- DOI